CDKN2A and pancreatic adenocarcinoma: In preclinical studies involving pancreatic adenocarcinoma cell cultures with a CDKN2A gene mutation, CDK4/6 inhibitors demonstrated antiproliferative activity against these cancer cells [39,40,41].